A Study Designed to Evaluate ODSH in Subjects With Exacerbations of COPD

• Status: Terminated
• Trial end date: 2009-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether ODSH, when added to conventional treatment, is more effective in treating COPD exacerbations than conventional therapy alone.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Cantex Pharmaceuticals; Chimerix
• Treatments: Heparin

Criteria

Inclusion Criteria:

1. Male and female patients (40 years of age or older) with an established diagnosis of COPD based upon medical history who are being admitted to the hospital to treat an exacerbation of COPD;

2. Normal prothrombin time and activated partial thromboplastin time; Platelet count; hemoglobin and hematocrit

Exclusion Criteria:

1. Certain diseases such as:

• asthma;

• left heart failure or pulmonary embolism;

• lung cancer;

• pneumonia

• liver or kidney disease

• blood clotting disorder

• Positive HIV or hepatitis tests

• GI bleeding, physical trauma with bleeding, any disease with bleeding within 60 days of study entry

2. Certain medications such as:

• Plavix®

• Warfarin

• Heparin therapy

• Certain antibiotics

3. Exacerbations that are too severe (requiring intubation and mechanical ventilation)

4. Women of child-bearing potential, pregnancy or breast-feeding

5. Unable or unwilling to provide informed consent and follow study procedures.